Paper ID: 2410.23628

Cycle-Constrained Adversarial Denoising Convolutional Network for PET Image Denoising: Multi-Dimensional Validation on Large Datasets with Reader Study and Real Low-Dose Data

Yucun Hou, Fenglin Zhan, Xin Cheng, Chenxi Li, Ziquan Yuan, Runze Liao, Haihao Wang, Jianlang Hua, Jing Wu, Jianyong Jiang

Positron emission tomography (PET) is a critical tool for diagnosing tumors and neurological disorders but poses radiation risks to patients, particularly to sensitive populations. While reducing injected radiation dose mitigates this risk, it often compromises image quality. To reconstruct full-dose-quality images from low-dose scans, we propose a Cycle-constrained Adversarial Denoising Convolutional Network (Cycle-DCN). This model integrates a noise predictor, two discriminators, and a consistency network, and is optimized using a combination of supervised loss, adversarial loss, cycle consistency loss, identity loss, and neighboring Structural Similarity Index (SSIM) loss. Experiments were conducted on a large dataset consisting of raw PET brain data from 1,224 patients, acquired using a Siemens Biograph Vision PET/CT scanner. Each patient underwent a 120-seconds brain scan. To simulate low-dose PET conditions, images were reconstructed from shortened scan durations of 30, 12, and 5 seconds, corresponding to 1/4, 1/10, and 1/24 of the full-dose acquisition, respectively, using a custom-developed GPU-based image reconstruction software. The results show that Cycle-DCN significantly improves average Peak Signal-to-Noise Ratio (PSNR), SSIM, and Normalized Root Mean Square Error (NRMSE) across three dose levels, with improvements of up to 56%, 35%, and 71%, respectively. Additionally, it achieves contrast-to-noise ratio (CNR) and Edge Preservation Index (EPI) values that closely align with full-dose images, effectively preserving image details, tumor shape, and contrast, while resolving issues with blurred edges. The results of reader studies indicated that the images restored by Cycle-DCN consistently received the highest ratings from nuclear medicine physicians, highlighting their strong clinical relevance.

Submitted: Oct 31, 2024